Abstract: Objective To explore the clinical efficacy of polyethylene glycol interferon combined with propofol tenofovir fumarate in the treatment of patients with chronic hepatitis B. Methods This study adopted a prospective research method and selected 131 patients with chronic hepatitis B admitted to our hospital from January 2021 to December 2022 for a single blind randomized trial. They were divided into a study group of 66 patients and a control group of 65 patients. The control group was treated with basic treatment and propofol tenofovir fumarate, while the study group added pegylated interferon to the treatment plan of the control group. The therapeutic effects were observed after 48 weeks of continuous treatment in both groups. Results Before treatment, there was no difference in serum levels of HBeAg, HBsAg, and HBV-DNA between the study group and the control group patients (P>0.05). After 24 and 48 weeks of treatment, the serum levels of HBeAg, HBsAg, and HBV-DNA in both groups decreased (P<0.05), with the study group showing a more significant decrease (P<0.05). There was no significant difference in the HBV-DNA conversion rate between the two groups of patients after 24 and 48 weeks of treatment (P>0.05). After 48 weeks of treatment, the HBeAg conversion rate in the study group was higher than that in the control group (P<0.05). Before treatment, two groups of serum levels of ALT, AST, IL-17, IL-4, and INF- α had no significant difference (P>0.05) and after 48 weeks of treatment, the serum levels of ALT, AST, IL-17, and IL-4 in both groups significantly decreased (P<0.05), and the serum level of INF- α was significantly increased (P<0.05). The serum levels of ALT, AST, IL-17, and IL-4 in the study group patients were significantly lower than those in the control group (P<0.05), and INF- α’s serum level increased more significantly when comparing to the control group (P<0.05). After 48 weeks of treatment, two groups’ clinical efficacy were evaluated. The overall efficacy of the study group was better than that of the control group, and the difference was statistically significant (P<0.05). Conclusion Polyethylene glycol interferon combined with propofol tenofovir fumarate in the treatment of chronic hepatitis B is conducive to reducing the levels of hepatitis B infection markers and inflammatory factors, which is generally conducive to improving the clinical treatment effect.

Key words: Polyethylene glycol interferon, Prophenofovir fumarate, Chronic hepatitis B, Antivirus, Virus load